(Q37202927)

English

A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants

scientific article published on 09 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants (English)

1 reference

Europe PubMed Central

18 August 2017

1 reference

based on heuristic

inferred from title

Bryce Chackerian

4

object named as

Bryce Chackerian

1 reference

Europe PubMed Central

18 August 2017

author name string

Ebenezer Tumban

1

1 reference

Europe PubMed Central

18 August 2017

Julianne Peabody

2

1 reference

Europe PubMed Central

18 August 2017

David S Peabody

3

1 reference

Europe PubMed Central

18 August 2017

language of work or name

0 references

publication date

9 August 2013

1 reference

Europe PubMed Central

18 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

18 August 2017

31

1 reference

Europe PubMed Central

18 August 2017

41

1 reference

Europe PubMed Central

18 August 2017

4647-4654

1 reference

Europe PubMed Central

18 August 2017

VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Understanding and learning from the success of prophylactic human papillomavirus vaccines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Arrangement of L2 within the papillomavirus capsid

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

A protective and broadly cross-neutralizing epitope of human papillomavirus L2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Chapter 17: Second generation HPV vaccines to prevent cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Maturation of papillomavirus capsids

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Efficient intracellular assembly of papillomaviral vectors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Epidemiologic classification of human papillomavirus types associated with cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Human papillomavirus and cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

6 September 2017

Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

14 September 2017

Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

3 September 2018

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

3 September 2018

Interior surface modification of bacteriophage MS2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3785330

3 September 2018

The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.052

7 January 2021

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.052

7 January 2021

Removal of endotoxin from protein solutions by phase separation using Triton X-114

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.052

7 January 2021

Toll-like receptor agonists as adjuvants for HIV vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.07.052

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.07.052

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37202927&oldid=2155368733"